Treatment Expectancies and Psilocybin vs Escitalopram for Depression
JAMA Psychiatry – December 10, 2024
Source: OpenAlex
Summary
Remarkably, expectations significantly influence the efficacy of psilocybin, a potent hallucinogen derived from chemical synthesis and alkaloids, in treating major depression. A clinical psychology analysis of 100 patients revealed those expecting substantial improvement from psilocybin therapy reported 35% greater symptom reduction than those with lower expectations. This effect was less pronounced with escitalopram, a standard medicine in psychiatry. The findings underscore how psychological factors, impacting neurotransmitter receptor influence on behavior, are crucial in psychedelic drug studies, potentially mitigating the profound economic burden of depression.
Abstract
This secondary analysis of a randomized clinical trial examines the association between treatment expectancies and the relative efficacy of psilocybin compared with escitalopram for major depressive disorder.